Wanbury Limited
WANBURY.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.86B
Close$
$-101.64
154.6% downside
Current Fair Value
154.6% downsideOvervalued by 154.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.86 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $20.48 |
| Beta | 1.26 |
| Outstanding Shares | 34,939,400 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 11.36 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Wanbury Limited
1,200 employees
CEO: Pradeep Patni Wanbury Limited, an Indian pharmaceutical company headquartered in Navi Mumbai, specializes in the manufacturing and sale of both finished pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company's diverse po...